Novartis Recalls Isopto Carpine Eye Drops for Impurity Failures
Novartis Pharmaceuticals is recalling specific lots of Isopto Carpine eye drops due to failed impurities and degradation specifications.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Novartis Pharmaceuticals Corp. is recalling Isopto Carpine (pilocarpine hydrochloride ophthalmic solution) 4%, packaged in 15 mL bottles. The recall involves Lot #244661F with an expiration date of February 2018. The product is a prescription-only medication manufactured by Alcon Laboratories, Inc.
The recall was initiated because the product failed impurities and degradation specifications. This indicates that the chemical composition of the eye drops did not meet the required quality standards for purity and stability.
Consumers and healthcare providers should stop using the affected product and return it to the pharmacy or point of purchase. The recall is classified as Class III by the FDA, which typically indicates that the product is unlikely to cause adverse health consequences.
The recalled product
- Product
- Isopto Carpine (pilocarpine hydrochloride opthalmic solution) 4%, packaged in 15 mL bottle, Rx only, Manufactured by: Alcon Laboratories, Inc. Fort Worth Texas 76134 USA NDC 0998-0206-15
- Manufacturer
- Novartis Pharmaceuticals Corp.
- Category
- Drug — Ophthalmic Solution
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 244661F
- Exp. Feb 2018
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Novartis Pharmaceuticals Corp. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Novartis Pharmaceuticals Corp.
See all →- SevereNovartis Withdraws SANDIMMUNE Oral Solution Bottles Due to Crystallization
FDA (Drugs) · 2023-09-27
- CriticalNovartis Recalls Promacta Oral Suspension Due to Peanut Cross-Contamination
FDA (Drugs) · 2019-05-29
- ModerateNovartis Recalls Pilocarpine Hydrochloride Ophthalmic Solution for Impurity Failures
FDA (Drugs) · 2017-05-03
- LowNovartis Recalls Dexmethylphenidate HCl Extended-Release Capsules for Dissolution Failure
FDA (Drugs) · 2015-09-23
- LowNovartis Recalls Foradil Aerolizer Due to Failed Stability Testing
FDA (Drugs) · 2015-06-24
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08